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or predictive significance, and finally low test­
­related cost.
The first report of increased platelet count in 
a patient with cancer dates back to 1872.2 Since 
then numerous studies investigating this phe­
nomenon have been published, and baseline plate­
let count has been acknowledged as a prognostic 
factor in patients with lung cancer. The use of this 
simple, inexpensive, and widely available marker 
is an attractive option. The relationship between 
platelet count and the survival of patients with 
some of the most common types of cancer, in­
cluding lung cancer, has been shown by Zhang et 
al.3 Furthermore, this indicator can be used dur­
ing diagnostic workup in lung cancer patients or 
as an indicator of lung metastasis.4,5
Although the issue has been investigated in 
several studies, it has not been fully elucidated so 
INTRODUCTION Lung cancer is the most com­
mon cause of cancer ­related death. In Poland, it 
is diagnosed in about 16 000 men and 6000 wom­
en every year.1 Because of its considerable preva­
lence, late diagnosis, and high mortality, as well as 
close relationship with tobacco smoking, it is un­
doubtedly a serious and unresolved health ­related 
problem. Numerous studies performed in recent 
decades resulted in considerable progress in diag­
nosis and treatment of lung cancer. Particularly, 
personalization of treatment, which means proper 
selection of therapy for specific patients, is gain­
ing increasing importance. While planning opti­
mal, individualized therapy, prognostic and pre­
dictive factors are crucial. They should be char­
acterized by several features, such as simplici­
ty and high availability, effectiveness in patient 
stratification, scientifically proven prognostic 
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ABSTRACT
INTRODUCTION Lung cancer is the most common cause of cancer ‑related death. Accurate and easy ‑to‑
‑use prognostic factors are necessary. Increased platelet count might be a potential prognostic factor.
OBJECTIVES We aimed to investigate the relationship between thrombocytosis and stage of lung cancer 
and to assess the frequency and clinical importance of thrombocytosis in this patient group.
PATIENTS AND METHODS We retrospectively analyzed hospital records of consecutive patients with 
non–small cell lung cancer (NSCLC) who underwent curative ‑intent pulmonary resections.
RESULTS Of 323 patients, 285 patients with NSCLC were selected (mean [SD] age, 66.55 [8.52] years; 
men, 63.86%). Squamous cell carcinoma was diagnosed in 130 patients (45.61%); adenocarcinoma, 
in 128 (44.91%); large cell carcinoma, in 16 (5.61%); and adenosquamous carcinoma, in 11 (3.86%). 
The prevalence of preoperative thrombocytosis in the whole sample was 10.18% (n = 29). Anemia was 
more common in patients with thrombocytosis compared with those without thrombocytosis (65.52% 
vs 30.08%; P <0.001). Thrombocytosis was found in 22.41% of patients with stage III+IV cancer and in 
3.82% of those with stage I (P <0.001). Moreover, in patients with no metastases (N0, M0 according to 
the 7th edition of the TNM classification), thrombocytosis was more frequent in the group with stage II 
than in that with stage I cancer (3.85% vs 20.00%; P = 0.002). Thrombocytosis was also more frequent 
in patients with N2 than with N1 disease (9.76% vs 23.81%; P = 0.09).
CONCLUSIONS Thrombocytosis is often observed in patients with NSCLC and is significantly associated 
with the higher stage of disease.
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endoscopic ultrasound. For the analysis, the fi­
nal, pathological stage was used.
The approval of the ethics committee was not 
required due to a retrospective study design (anal­
ysis of hospital records).
Statistical analysis Statistica 12.0 software (Stat­
Soft, Statistica 12.0, Tulsa, Oklahoma, United 
States) was used for statistical analysis. Con­
tinuous data were presented as mean and stan­
dard deviation (SD) or median and interquar­
tile range (IQR), and qualitative data, as num­
bers and percentages. The χ2 test and Fisher test 
were used to compare qualitative data, while 
the t test, Mann–Whitney test, and analysis of 
variance were used for quantitative data. Continu­
ous variables were first checked for normal distri­
bution by the Shapiro–Wilk test. For the analysis 
of variables with other than normal distribution, 
the Mann–Whitney test was used and the values 
were presented as median and IQR; data with nor­
mal distribution were analyzed with the t test. 
To compare more than 2 groups, the analysis of 
variance with proper corrections was performed. 
The MedCalc statistical online calculator was used 
for estimation diagnostic test parameters. For all 
tests, a P value less than 0.05 was considered sig­
nificant. Patients with missing specific data were 
not included in further analysis.
RESULTS The  clinicopathologic characteris­
tics of patients are shown in TABLE 1. The total 
number of patients collected between 30 June 
far. Moreover, to our knowledge, none of the stud­
ies have involved the Polish population. In our 
study, we aimed to investigate the relationship 
between thrombocytosis and stage of non–small 
cell lung cancer (NSCLC) and to assess the fre­
quency and clinical importance of thrombocyto­
sis in this patient group.
PATIENTS AND METHODS This retrospective 
study was conducted in the Department of Tho­
racic Surgery, John Paul II Hospital, Kraków, Po­
land. The study group included consecutive pa­
tients with NSCLC who underwent a curative­
­intent pulmonary resection between September 
2015 and December 2016. Data used for analysis 
were obtained from medical records. The following 
variables were recorded: patients’ demographics, 
cancer stage, grade, histological type, and lymph 
node metastases, platelet count, hemoglobin con­
centration, comorbidities, and smoking habit.
Thrombocytosis was assessed from the last 
whole blood count obtained before the surgery 
and was defined as a platelet count higher than 
400 000/µl. Preoperative hemoglobin concentra­
tions were also measured, with anemia being de­
fined as a hemoglobin concentration of less than 
12 g/dl for women and less than 13.5 g/dl for men. 
The stage of lung cancer was based on the 7th edi­
tion of the TNM classification. Each patient un­
derwent preoperative staging, including chest 
radiography, computed tomography, positron­
­emission tomography combined with comput­
ed tomography, endobronchial ultrasound, and 
TABLE 1 Clinicopathological characteristics of the study group
Variable All patients Patients with 
thrombocytosis 
Patients with normal 
platelet count 
P valuec
Total number of patients with NSCLC, n (%) 285 (100) 29 (10.18) 256 (89.82) –
Women, n (%) 103 (36.14) 13 (44.83) 90 (35.16) 0.41
Men, n (%) 182 (63.86) 16 (55.17) 166 (64.84)
Age, median (IQR) 66 (62.00–72.00) 64 (60.00–70.00) 67 (62.00–72.00) 0.17
Age ≥65 years, n (%) 176 (61.75) 14 (48.28) 162 (63.28) 0,17
Smoking, n (%) 179 (62.81) 20 (74.07a) 159 (62.85b) 0.17
COPD, n (%) 44 (15.44) 4 (14.81a) 40 (15.81b) 0.58
Diabetes, n (%) 49 (17.19) 3 (11.11a) 46 (18.18b) 0.27
Histological type, n (%) SCC 130 (45.61) 14 (48.28) 116 (45.31) 0.97
ADC 128 (44.91) 12 (41.38) 116 (45.31)
LCC 16 (5.61) 2 (6.90) 14 (5.47)
Adenosquamous 
carcinoma
11 (3.86) 1 (3.45) 10 (3.91)
PLT, × 103/µl, median (IQR) 254.00 (211.00–319.00) 449.00 (423.00–546.00) 249.50 (208.00–292.00) <0.001
Hemoglobin, g/dl, median (IQR) 13.40 (12.80–14.20) 11.30 (9.90–13.20) 13.50 (12.80–14.35) <0.001
Anemia (hemoglobin concentration <13.5 g/dl 
for men, <12.0 g/dl for women), n (%)
96 (33.68) 19 (65.52) 77 (30.08) <0.001
Neoadjuvant chemotherapy 8 (2.81) 0 8 (3.13) –
a Missing data of 2 patients;   b Missing data of 3 patients;  c Patients with thrombocytosis vs patients with normal platelet count
Conversion factors to SI units: to convert hemoglobin to g/l, multiply by 10.0, platelet count to × 109/l, multiply by 1.0.
Abbreviations: ADC, adenocarcinoma; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; LCC, large‑cell carcinoma; NSCLC, 
non–small cell lung cancer; PLT, platelet count; SCC, squamous cell carcinoma
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The results of analyses according to the stages 
of lung cancer are presented in TABLE 2. Stage distri­
bution in the overall study group was as follows: 
stage IA, 98 patients (34.39%); IB, 59 (20.70%); 
IIA, 41  (14.39%); IIB, 29  (10.18%); IIIA, 
49 (17.19%); IIIB, 1 (0.35%); and IV, 8 (2.81%). 
The platelet count at different stages of disease 
are presented in FIGURE 2. Thrombocytosis was more 
frequently diagnosed in the combined group of 
patients with III+IV stages of disease (13 [22.41]; 
P <0.001) than in stage I (6 [3.82]) and stage II 
(10 [14.29]). Similar association was observed 
also in the case of thrombocytosis without ane­
mia (TABLE 2). However, there was no case of throm­
bocytosis without anemia in stage II. There was 
no difference in the prevalence of thrombocyto­
sis between stages IIB and IIIA (6 [20.69%] vs 
10 [20.41%]; P = 0.60). However, patients in group 
IIIA more often had thrombocytosis than patients 
with stage I (10 [20.41%] vs 6 [3.82%]; P <0.001) 
and had a higher median platelet count (276 [IQR, 
242–381] vs 245 [IQR, 207–286]; P <0.001).
A separate analysis was performed in patients 
with no metastases (N0, M0) stage I (IA+IB) and 
II (IIA+IIB). In stage II, thrombocytosis was more 
frequent than in stage I (8 [20.00%] vs 6 [3.85%]; 
P = 0.002). Stage II was also characterized by 
a higher median platelet count (285.50 × 103/µl 
[IQR, 214.00–364.50] vs 245.00 × 103/µl [IQR, 
206.50–287.50]; P = 0.01)
The analysis of a histological grade of the tumor 
showed grade I in 15 cases; grade II in 160; grade 
III, in 86; and grade IV, in 21. There was no associ­
ation between tumor grade and thrombocytosis.
Data of patients with N0, N1, and N2 involve­
ment are presented in TABLE 3. There were no signif­
icant differences between N0 and N1 patients in 
the prevalence of thrombocytosis and thrombo­
cytosis without anemia. However, patients with 
N2 disease significantly more often had thrombo­
cytosis and thrombocytosis without anemia than 
those with N0 disease. There was no such asso­
ciation in a direct comparison between N2 and 
N1 patients. The evaluation of thrombocytosis 
2017 and 15 November 2017 was 323. The histo­
logical types of NSCLC were squamous cell car­
cinoma (SCC) in 130 cases (40.2%); adenocarci­
noma (ADC), in 128 (39.63%); large cell carcino­
ma (LCC), in 16 (4.95%); adenosquamous carci­
noma, in 11 (3.41%); carcinoid, in 22 (6.81%); 
pulmonary metastases in 4 (1.24%); and other 
malignant tumors, in 12 (3.71%).
Because of different pathology, carcinoids, 
lung metastases, and other tumors were ex­
cluded. This resulted in a homogenous group of 
285 patients with SCC, ADC, adenosquamous 
carcinoma, and LCC, whose data were included 
in the final analysis (FIGURE 1). The mean (SD) age 
of the study group was 66.55 (8.52) years (range, 
29–88 years), and there were 182 men (63.86%). 
Active smoking was reported by 179 patients 
(62.81%); chronic obstructive pulmonary disease 
was observed in 44 patients (15.44%) and dia­
betes in 49 (17.19%). Prior neoadjuvant chemo­
therapy was administered in 8 patients (2.81%). 
The median platelet count was 254×103/µl (IQR, 
211–319; min–max, 119.00–806×103/µl). Me­
dian hemoglobin concentration was 13.4 g/dl 
(IQR, 12.80–14.20).
The prevalence of preoperative thrombocy­
tosis was 10.18% (29 patients). The compari­
son of groups with and without thrombocyto­
sis is shown in TABLE 1. There were no differenc­
es between groups in terms of sex, age, chron­
ic obstructive pulmonary disease, diabetes, and 
histological type of cancer. Preoperative anemia 
was significantly more common (19 [65.52%] vs 
77 [30.08%]; P <0.001) as well as median hemo­
globin concentrations were lower (P <0.001) in pa­
tients with thrombocytosis. There were no differ­
ences between patients with and without throm­
bocytosis in terms of the smoking habit. There 
was no relationship between histological type of 
cancer and smoking habit. The number (percent­
age) of smokers and nonsmokers was 87 (48.60%) 
and 41 (40.59%), respectively, in the SCC group 
(P = 0.20) and 75 (41.90%) and 51 (50.50%), re­
spectively, in the ADC group (P = 0.17).
FIGURE 1 Distribution 
of study participants 
depending on 
the histological type of 
the tumor. Data are 
shown as number 
(percentage) of patients. 
Abbreviations: see 
TABLE 1
Total number of 
patients 
323 (100)
Carcinoid 
22 (6.81) 
Metastases 
4 (1.24) 
Other malignant tumors 
12 (3.71)
NSCLC 
285 (88.24)
Adenosquamous 
carcinoma 
11 (3.86)
ADC 
128 (44.91)
SCC 
130 (45.61)
LCC 
16 (5.61)
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the results obtained in previous studies on com­
parable groups with identical thrombocytosis 
cutoff values.6,7
The mechanism underlying increased plate­
let count in patients with cancer and the asso­
ciation of high platelet count with worse prog­
nosis are still poorly understood. Under physio­
logical conditions, the production of platelets in 
the bone marrow is mainly stimulated by throm­
bopoietin. In cancer, the tumor affects thrombo­
poiesis through some alternative factors, such as 
interleukin (IL) 1, IL ­3, IL ­6, and IL ­11, fibroblast 
growth factor, and erythropoietin.8 The produc­
tion of so many cytokines and elevated platelet 
as a diagnostic test for metastases in N2 lymph 
nodes was characterized by a sensitivity of 23.81% 
(95% CI, 12.05%–39.45%), specificity of 92.18% 
(95%CI, 88.06%–95.23%), positive predictive val­
ue of 34.48% (20.85%–51.26%), and negative pre­
dictive value of 82.11% (95% CI, 77.15%–86.38%).
DISCUSSION Numerous studies evaluated throm­
bocytosis in patients with malignancy; however, 
only a few of them included patients with less ad­
vanced stages of lung cancer. Furthermore, none 
of them was performed in the Polish population.
In our group, the frequency of preoperative 
thrombocytosis was 10.18%, which is similar to 
FIGURE 2 Differences 
in mean platelet (PLT) 
count depending on 
the stage of non–small 
cell lung cancer (NSCLC)
TABLE 2 Relations between the stage of non–small cell lung cancer and thrombocytosis with or without anemia and the platelet count
Parameter NSCLC stage          P value
              I                II                        III+IV
IA IB IIA IIB IIIA IIIB IV
Total number of 
patients, n
98 59 41 29 49 1 8 –
Patients with 
thrombocytosis, 
n (%)
5 (5.10) 1 (1.69) 4 (9.76) 6 (20.69) 10 (20.41) 1 (100.0) 2 (25.00) <0.001
6 (3.82) 10 (14.29) 13 (22.41) <0.001
Patients with 
thrombocytosis 
without anemia, 
n (%)
3 (1.91) 0 7 (12.07) <0.001
PLT, × 103/µl, 
median (IQR)
244.50 (205.00–
291.00)
250.00 (208.00–
286.00)
269.00 (209.00–
337.00)
247.00 (221.00–
347.00)
276.00 (242.00–
381.00)
402.00a 318.00 (264.50–
387.00)
<0.001
   245.00 (207.00–286.00) 269.50 (210.00–343.00)            285.00 (242.00–382.00) <0.001
Hemoglobin, g/dl, 
median (IQR)
13.50  
(12.80–14.50)
13.80  
(13.00–14.70)
13.20  
(12.60–13.90)
12.70  
(11.70–14.00)
13.40  
(12.10–14.10)
12.9a 13.30  
(12.40–14.10)
0.001
   13.70 (12.90–14.60) 13.10 (12.10–13.90)              13.40 (12.20–14.10) <0.001
a Data of a single patient
Abbreviations: OR, odds ratio; others, see TABLE 1
I II III+IV
NSCLC stage
220
230
240
250
260
270
280
290
300
310
320
330
340
350
PL
T 
co
un
t, 
×1
03
/μ
l
 Mean ±95%  CI
 P <0.001
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explained by their very similar etiology in cancer 
patients. Anemia and thrombocytosis are types 
of paraneoplastic syndromes, which often indi­
cate advanced cancer.21
Similarly to other authors,22 we observed a high­
er frequency of thrombocytosis associated with 
more advanced stage of the disease. Moreover, 
we showed that the frequency of thrombocyto­
sis is higher in N2 disease. In the N0M0 group, 
the chance of thrombocytosis was significant­
ly higher when the primary tumor was more ad­
vanced. These observations may be clinically im­
portant. The diagnosis of thrombocytosis in a pa­
tient with lung cancer can suggest a higher stage of 
the disease and is a negative prognostic factor. In 
our group, the presence of thrombocytosis showed 
high specificity in the diagnosis of N2 disease.
In our study, none of the patients who under­
went preoperative chemotherapy had thrombo­
cytosis. Thrombocytopenia is a frequent adverse 
event of treatment with platinum ­based regimens 
and gemcitabine.23 It is likely that the effect of 
chemotherapy is a confounding factor and that 
the prognostic value of thrombocytosis is thus 
low in these patients. On the other hand, because 
of the small number of patients who underwent 
neoadjuvant chemotherapy in our study, this hy­
pothesis should be confirmed in further research.
Similarly to Bailey et al,4 we believe that evalua­
tion of thrombocytosis may be a useful tool in ev­
eryday practice in oncology and thoracic surgery, 
although its significance is neglected. The diagno­
sis of this blood clotting disorder could prompt 
a more detailed diagnosis, particularly if found 
in a patient with N0, M0 tumors.
The study has several limitations, it was a ret­
rospective study and, although the overall num­
ber of patients was relatively large, the individ­
ual subgroups were small. Another limitation is 
a single preoperative measurement of complete 
blood count, without subsequent measurements.
In conclusion, due to its low cost and wide 
availability, assessment of thrombocytosis may be 
a useful tool in preoperative screening of lung can­
cer patients. Thrombocytosis is associated with 
more advanced stage of the disease and N2 dis­
ease. In this study, thrombocytosis often coex­
isted with anemia. Large prospective studies are 
needed to further evaluate the role of thrombo­
cytosis in lung cancer.
count facilitate and accelerate the progression 
of cancer.9 Platelets directly protect cancer cells 
against contact with the host’s immune system, 
reduce the activity of natural killer cells (which 
are responsible for the elimination of tumor­
­transformed cells)10,11, facilitate transport of 
cancer cells to other places in the patient’s body 
and development of metastases,9 and accelerate 
neoangiogenesis.12 On the basis of these stud­
ies, an interplay between cancer cells and plate­
lets has been proposed, in which platelets are 
involved not only in blood coagulation process. 
However, impaired hemostatic function and rela­
tionships with different components of the blood 
clotting system have been studied mainly in he­
matologic diseases, such as essential thrombocy­
themia.13 Moreover, a method of treatment un­
doubtedly has an effect on hematologic changes 
and the immune system. For example, stereotactic 
ablative radiotherapy used in NSCLC may influ­
ence white blood cell count.14 The effect of surgical 
procedures on thrombocytosis is not well known.
To avoid confounding factors related to dif­
ferent biology of cancer, we analyzed only pa­
tients with NSCLC: ADC, SCC and LCC, for which 
the most effective treatment modality is surgery 
in early stages.15,16 However, there were some dif­
ferences in the rates of the histological types, with 
most patients having SCC and ADC (with simi­
lar distribution). Other studies reported differ­
ent rates for the various types,6,17,18 but there is 
a notable trend for increased incidence of ADC.15 
We did not observe an association between an in­
creased frequency of thrombocytosis and differ­
ent histological types of lung cancer. This finding 
is in line with the report by Maraz et al.17
Smoking is recognized as the main risk factor 
for lung cancer. Smokers were predominant in 
our study group, which is in line with the results 
of other authors.18 Maraz et al17 reported a high­
er incidence of thrombocytosis in smokers, but 
this association was not confirmed in our study.
The most common hematologic abnormalities 
with confirmed negative prognostic value in pa­
tients with lung cancer include anemia, throm­
bocytosis, and leukocytosis.6,7,19,20 Some patients 
in our study had coexisting anemia and throm­
bocytosis. To the best of our knowledge, this is 
the first report to show simultaneous presence of 
these 2 hematologic abnormalities. This may be 
TABLE 3 Concomitance of thrombocytosis and lymph node metastases in patients with non–small cell lung cancer
N0 N1 P value (N0 vs N1) N2 P value (N1 vs N2) P value (N0 vs N2)
Total number of patients, n (%) 202 (70.88) 41 (14.39) – 42 (14.74) – –
Patients with thrombocytosis, n (%) 15 (7.43) 4 (9.76) 0.40 10 (23.81) 0.09 0.001
Patients with thrombocytosis without 
anemia, n (%)
3 (1.49) 1 (2.44) 0.53 6 (14.29) 0.06 0.001
Histological type 
of NSCLC, n (%)
SCC 88 (43.56) 21 (51.22) 0.02 21 (50.00) 0.18 0.75
ADC 98 (48.51) 12 (29.27) 18 (42.86)
Other types 16 (7.92) 8 (19.51) 3 (7.14)
Abbreviations: see TABLES 1 and 2
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19 Gislason T, Nõu E. Sedimentation rate, leucocytes, platelet count and 
haemoglobin in bronchial carcinoma: an epidemiological study. Eur J Respir 
Dis. 1985; 66: 141‑146.
20 Tomita M, Shimizu T, Hara M, et al. Impact of preoperative hemoglobin 
level on survival of non ‑small cell lung cancer patients. Anticancer Res.2008; 
28: 1947‑1950.
21 Kanaji N, Watanabe N, Kita N, et al. Paraneoplastic syndromes associ‑
ated with lung cancer. World J Clin Oncol. 2014; 5: 197‑223. 
22 Pedersen LM, Milman N. Prognostic significance of thrombocytosis in 
patients with primary lung cancer. Eur Respir J. 1996; 9: 1826‑1830. 
23 Kuter DJ. Managing thrombocytopenia associated with cancer chemo‑
therapy. Oncology (Williston Park). 2015; 29: 282‑294.
CONTRIBUTION STATEMENT PS conceived 
the concept of the study. PS, JH, and JK con­
tributed to the design of the research. KS searched 
for references. PS, KS, MF, and JH were involved 
in data acquisition. PS analyzed the data. KS and 
MF interpreted the data. JK supervised data pro­
cessing. All authors were involved in drafting and 
revising the article. All authors approved the fi­
nal version of the manuscript.
OPEN ACCESS This is an Open Access article dis­
tributed under the terms of the Creative Com­
mons Attribution NonCommercial ShareAlike 
4.0 International License (CC BY ­NC ­SA 4.0), 
allowing third parties to copy and redistribute 
the material in any medium or format and to re­
mix, transform, and build upon the material, pro­
vided the original work is properly cited, distrib­
uted under the same license, and used for non­
commercial purposes only. For commercial use, 
please contact the journal office at pamw@mp.pl.
REFERENCES
1 Wojciechowska U, Didkowska J, Maria Skłodowska ‑Curie Institute of 
Oncology. [Illnesses and deaths from malignant tumors in Poland. National 
Cancer Registry]. Polish. http://onkologia.org.pl/raporty/. Accessed March 
15, 2018.
2 Riess L. Zur pathologischen Anatomie des Blutes. Arch Anat Physiol 
Wissensch Med. 1872; 39: 237‑249.
3 Zhang X, Lv Z, Yu H, Zhu J. The clinicopathological and prognostic role of 
thrombocytosis in patients with cancer: a meta ‑analysis. Oncol Lett. 2017; 
13: 5002‑5008. 
4 Bailey S, Ukoumunne O, Shephard E, Hamilton W. How useful is throm‑
bocytosis in predicting an underlying cancer in primary care? A systematic 
review. Family Practice. 2017; 34: 4‑10. 
5 Iwasaki A, Hamanaka W, Harnada T, et al. Significance of platelet counts 
in patients who underwent surgical treatment for lung metastasis. Int Surg. 
2007; 92: 103‑109.
6 Kim M, Chang H, Yang HC. Preoperative thrombocytosis is a significant 
unfavorable prognostic factor for patients with resectable non ‑small cell lung 
cancer. World J Surg Oncol. 2014; 12: 37. 
7 Tomita M, Shimizu T, Hara M, et al. Prognostic impact of thrombocyto‑
sis in resectable non ‑small cell lung cancer. Interact Cardiovasc Thorac Surg. 
2008; 7: 613‑615. 
8 Buergy D, Wenz F, Groden C, Brockmann MA. Tumor ‑platelet interaction 
in solid tumors. Int J Cancer. 2012; 130: 2747‑2760. 
9 Gay LJ, Felding ‑Habermann B. Contribution of platelets to tumour metas‑
tasis. Nat Rev Cancer. 2011; 11: 123‑134. 
10 Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor 
cells by natural killer cells in mice is impeded by platelets. Cancer Res. 
1999; 59: 1295‑1300.
11 Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin(ogen) 
increase metastatic potential by impeding natural killer cell ‑mediated elimi‑
nation of tumor cells. Blood. 2005; 105: 178‑185. 
12 Italiano JE Jr, Richardson JL, Patel ‑Hett S, et al. Angiogenesis is reg‑
ulated by a novel mechanism: pro‑ and antiangiogenic proteins are orga‑
nized into separate platelet alpha granules and differentially released. Blood. 
2008; 111: 1227‑1233.
13 Stankowska K, Gadomska G, Boinska J, et al. Extrinsic blood coagula‑
tion pathway and risk factors for thrombotic events in patients with essen‑
tial thrombocythemia. Pol Arch Med Wewn. 2016; 126: 340‑346.
14 Rutkowski J, Ślebioda T, Kmieć Z, Zaucha R. Changes in systemic im‑
mune response after stereotactic ablative radiotherapy: preliminary results 
of a prospective study in patients with early lung cancer. Pol Arch Intern 
Med. 2017; 127: 245‑253.
15 Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiol‑
ogy, and prevention. Clin Chest Med. 2011; 32: 605‑644. 
16 Zarogoulidis K, Zarogoulidis P, Darwiche K, et al. Treatment of non ‑small 
cell lung cancer (NSCLC). J Thorac Dis. 2013; 5: 389‑396.
17 Maraz A, Furak J, Varga Z. Thrombocytosis has a negative prognostic 
value in lung cancer. Anticancer Res. 2013; 33: 1725‑1729.
18 Baburao A, Narayanswamy H. Clinico ‑pathological profile and hae‑
matological abnormalities associated with lung cancer in Bangalore, India. 
Asian Pac J Cancer Prev. 2015; 16: 8235‑8238. 
